RFC1 and mild neurocognitive disorder: Therefore, in this study, we conducted a systematic screening for RFC1 expansions in a cohort of 107 patients with MND primarily composed of ALS patients employing CRISPR/Cas9-targeted Oxford nanopore technology (ONT) long-read sequencing [4, 19].